{"id":9,"date":"2018-11-18T22:54:42","date_gmt":"2018-11-19T02:54:42","guid":{"rendered":"https:\/\/www.creativebiomart.net\/alzheimacy\/?page_id=9"},"modified":"2020-09-06T23:52:33","modified_gmt":"2020-09-07T03:52:33","slug":"target","status":"publish","type":"page","link":"https:\/\/www.creativebiomart.net\/alzheimacy\/target\/","title":{"rendered":"Target"},"content":{"rendered":"

Approved Alzheimer\u2019s Drugs and Their Targets <\/strong><\/p>\n

Currently, four drugs are approved for the treatment of Alzheimer\u2019s Disease (AD). Among them, there are three inhibitors targeting acetylcholinesterase (AChE), Donepezil, Rivastigmine and Galantamine\u00a0respectively. The role of these drugs is to block the downregulation of the neurotransmitter acetylcholine (ACh), a crucial signaling molecule\u00a0for nerve cells communication.\u00a0The last approved AD drug, Memantine, regulates glutamate activity in the brain of patients with AD by blocking the N-methyl-D-aspartate (NMDA) receptor.<\/p>\n\n\n\n\n\n\n\n
Approved Drug <\/strong><\/td>\nStructure <\/strong><\/td>\nTarget <\/strong><\/td>\nEffect <\/strong><\/td>\n<\/tr>\n
Donepezil<\/td>\n<\/td>\nAcetylcholinesterase<\/td>\n\n
    \n
  • Noncompetitive Reversible Inhibitor of AChE<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
Rivastigmine<\/td>\n<\/td>\nAcetylcholinesterase<\/td>\n\n
    \n
  • Inhibitor of AChE<\/li>\n
  • Inhibitor of Butyrylcholinesterase (BuChE)<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
Galantamine<\/td>\n<\/td>\nAcetylcholinesterase<\/td>\n\n
    \n
  • Selective Reversible Inhibitor of AChE<\/li>\n
  • Positive Allosteric Modulator of Nicotinic ACh Receptors<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
Memantine<\/td>\n<\/td>\nNMDA Receptor<\/td>\n\n